• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News > New DNDi report: Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations  > Page 14

New DNDi report: Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations 

Home > News > New DNDi report: Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations  > Page 14

New DNDi report: Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations 

Geneva, Switzerland — 17 Nov 2025

The Drugs for Neglected Diseases initiative (DNDi) is pleased to announce the publication of its new policy report, Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations. 

Building on DNDi’s more than 20 years of experience developing treatments for neglected populations, the report explores how open and collaborative science, including a pro-access approach to managing intellectual property, can accelerate innovation, promote knowledge sharing, and ensure that life-saving health technologies are affordable and accessible to all who need them. 

The report provides one of the first comprehensive looks at how openness can be operationalized in real-world R&D collaborations. In particular, it examines: 

  • The tensions and trade-offs between open science and more traditional, proprietary biomedical research models; 
  • DNDi’s continuum of open science approaches, ranging from bilateral partnerships with industry to more open-source collaborations such as the Open Synthesis Network and the COVID-19 Moonshot; 
  • Case studies exploring how open science approaches were navigated in specific DNDi projects and partnerships; 
  • A practical framework for embedding openness and equitable access across the innovation lifecycle based on DNDi’s experience; and 
  • Actionable recommendations for governments, R&D funders, academia and other research organizations, and industry to operationalize openness and equity in their innovation policies, practices, and partnerships. 

And it comes at a critical time: on the one hand, major funding cuts to medical research and growing geopolitical tensions are threatening fragile gains in global health. On the other hand, there are potentially transformative technological advances in biomedicine, renewed calls for stronger and more self-sufficient innovation ecosystems, especially in low- and middle-income countries, and an emerging consensus, including in the Pandemic Agreement, about how governments can leverage the power of public R&D funding to shape health innovation outcomes so that greater openness and equitable access are ensured. 

Open science in a closed world makes the case that research knowledge should be viewed not as a commodity to be enclosed, but as a shared resource essential to achieving more equitable health outcomes and argues that greater openness must move from aspiration to implementation—making open sharing of knowledge, data, and know-how as well as equitable access core objectives of R&D. 

DNDi invites policymakers, funders, researchers, and advocates to join the discussion and help translate the report’s recommendations into concrete action. 

download the report

Join the conversation: Share your reflections on social media!

access the toolkit

Photo credit: Thoko Chikondi-DNDi

Policy advocacy

Read, watch, share

Loading...
The Kissing Bug Doctors of Florida poster
Videos
14 Apr 2024

The Kissing Bug Doctors of Florida

Three scientists
Press releases
3 Apr 2024

DNDi signs memorandum of understanding with Kenya Medical Research Institute

Doctor and patient
News
2 Apr 2024

Ravidasvir journey

Lab activities
News
1 Apr 2024

Pandemic preparedness: DNDi and THSTI receive financial support from Novo Nordisk Foundation to develop broad-spectrum, host-directed antivirals

Person putting on PPE
News
28 Mar 2024

2023 R&D portfolio in review: Pandemic preparedness

News
28 Mar 2024

2023 R&D portfolio in review: Chagas

Woman and man sitting
News
28 Mar 2024

2023 R&D portfolio in review: Hepatitis C

Doctor standing outside hospital
News
28 Mar 2024

2023 R&D portfolio in review: HIV

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license